Business
Sevion Therapeutics Announces Chimerasome Research Agreement
Sevion Therapeutics Announces Chimerasome Research Agreement.
About this update from Eloxx Pharmaceuticals, Inc.
[{"type":"text","content":"\n \n Sevion Therapeutics (OTCQB:SVON), a biopharmaceutical company which \n discovers, develops and acquires next-generation biologics for the \n treatment of cancer and immunological diseases, today announced that it \n has entered into a research agreement with Avidity NanoMedicines LLC \n related to the use of Sevion’s chimerasome technology for delivery of \n nucleic acids. Terms of the agreement were not disclosed.\n \n \n The Chimerasome, which is based on a single protein that can be \n assembled to form a spherical protein nanocage encapsulating drugs or \n nucleic acid therapeutics, can be decorated with antibodies or peptides \n externally, enabling highly specific cellular targeting of the payload.\n \n \n “The Chimerasome biologics approach allows for specific optimization of \n regions of the building block responsible for the key functions required \n for a successful delivery system, including serum stability, triggered \n opening and payload release, tunable PK and biodistribution, as well as \n safety,” said Ronald Martell, CEO of Sevion Therapeutics. “This \n collaboration is a key example of our effort to leverage our pipeline \n and platforms through partnership, while we look to advance our internal \n antibody pipeline and explore in-licensing opportunities.”\n \n \n About Sevion Therapeutics\n \n \n Sevion Therapeutics is a biopharmaceutical company building and \n developing a portfolio of innovative therapeutics, from both internal \n discovery and acquisition, for the treatment of cancer and immunological \n diseases. The Company’s product candidates are derived from multiple key \n proprietary technology platforms: cell-based arrayed antibody discovery, \n ultralong antibody scaffolds and Chimerasome nanocages. Sevion has \n leveraged these technologies to build a pipeline of innovative product \n candidates. For more information, please visit SevionTherapeutics.com.\n \n \n About Avidity NanoMedicines\n \n \n Avidity NanoMedicines is pioneering a new class of therapeutics, \n antibody-siRNA complexes (ARCs™), which employ antibody-targeted \n nanoparticles containing siRNA payloads. The technology draws on the \n targeting associated with antibody-drug conjugates and the selectivity \n of nucleic acid-based medicines. Through partnerships with academic a...